DRUG
MECHANISM
USE
ADVERSE · NOTES
Reversible COX-1 and COX-2 inhibition
Pain, fever, inflammation, dysmenorrhea, gout
GI bleeding, AKI, ↑ BP, HF exacerbation; ibuprofen blocks aspirin's antiplatelet effect
Potent nonselective COX inhibitor
PDA closure, acute gout, pericarditis, hemicrania, preterm labor
GI, renal toxicity, headache
Parenteral NSAID
Short-term severe pain (≤ 5 days), renal colic
High GI/renal risk
Selective COX-2 inhibitor
Arthritis in GI-bleed-risk patients
↑ MI/stroke (↓ PGI₂, TXA₂ intact), sulfa allergy, renal effects
Irreversible COX-1 acetylation in platelets
ACS, secondary prevention, preeclampsia prevention
GI bleed; Reye syndrome in children
COX-1/2 inhibition; uricosuric at very high dose, retains urate at low dose
Rheumatic fever, Kawasaki (with IVIG)
Tinnitus, hearing loss, metabolic acidosis
Stimulates respiratory center; uncouples oxidative phosphorylation
Early respiratory alkalosis → mixed AG acidosis; hyperthermia, tinnitus, AMS
Sodium bicarbonate (alkalinize urine), glucose, hemodialysis
Central COX inhibition (weak peripherally)
Pain and fever; children (no Reye risk); pregnancy
Hepatotoxicity > 4 g/day or less with alcohol, malnutrition
CYP2E1 → NAPQI; glutathione depleted
Nausea day 1, ↑ LFTs day 2–3, liver failure day 3–5
N-acetylcysteine (best < 8 h); nomogram uses 4-h level
↓ PGE₂/PGI₂ → afferent constriction; ↓ renin
AKI in volume-depleted, CKD, HF, cirrhosis, ACEi users
Hyperkalemia, type 4 RTA-like state, AIN, papillary necrosis
Fetal prostaglandins keep ductus open, support fetal kidney
Avoid after 20 weeks (oligohydramnios), after 30 weeks (ductus closure)
Acetaminophen preferred
Aspirin-exacerbated respiratory disease
COX block shunts arachidonic acid to leukotrienes
Asthma + nasal polyps + NSAID sensitivity
Montelukast, aspirin desensitization